

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): October 29, 2024**

---

**CRYO-CELL INTERNATIONAL, INC.**

(Exact name of Registrant as Specified in Its Charter)

---

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-40767**  
(Commission File Number)

**22-3023093**  
(IRS Employer  
Identification No.)

**700 Brooker Creek Blvd.**  
**Oldsmar, Florida**  
(Address of Principal Executive Offices)

**34677**  
(Zip Code)

**Registrant's Telephone Number, Including Area Code: 813 749-2100**

(Former Name or Former Address, if Changed Since Last Report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.01 par value	CCEL	NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On October 29, 2024, the Company held its Annual Meeting of Stockholders. At the Annual Meeting, stockholders considered the election of four directors, the ratification of the Company's independent registered accountants and the approval of a non-binding advisory resolution regarding the compensation of the Company's named executive officers

The final result of the stockholder vote was certified on October 29, 2024 and is as follows:

1. To consider the election of four individuals to the Company's Board of Directors.

David Portnoy		
For	3,653,908	
Withhold	789,479	

Harold Berger		
For	3,628,143	
Withhold	815,244	

Mark Portnoy		
For	3,649,613	
Withhold	793,774	

Daniel Mizrahi		
For	4,072,486	
Withhold	370,901	

2. The ratification of appointment of WIPFLI LLC as the Company's independent registered public accounting firm for the fiscal year ending November 30, 2024.

For	Against	Abstain
6,697,620	186	3,536

3. The approval of a non-binding advisory resolution regarding the compensation of the Company's named executive officers.

For	Against	Abstain
4,152,942	287,390	3,055

4. Authorization to vote the proxies upon other business properly coming before the Meeting or any adjournments or postponements thereof.

For	Against	Abstain
3,571,034	855,538	16,814

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Cryo-Cell International, Inc.

Date: October 31, 2024

By: /s/ David Portnoy  
David Portnoy, Chairman and Co-CEO

---

